Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Vandetanib

FDA-approved product (tablet, oral), marketed as Caprelsa.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Vandetanib
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cancer
  • Medullary thyroid gland carcinoma
  • Neoplasm
  • Papillary thyroid carcinoma
  • Thyroid cancer
  • Thyroid carcinoma
  • Thyroid neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other protein kinase inhibitors
FDA pharmacologic class
Kinase Inhibitor FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA58.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli52.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae36.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis67.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Vandetanib in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.7 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Vandetanib with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).

    NCT04760288 · start 2023-11-30

    Registered record
    Registry ID
    NCT04760288
    Conditions
    Medullary Thyroid Cancer
    Interventions
    Pralsetinib; Cabozantinib; Vandetanib
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2023-11-30
    Completion
    2035-04-12
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMedullary Thyroid Cancer
    InterventionPralsetinib; Cabozantinib; Vandetanib
    PhasePhase 3
    Registry statusWithdrawn

  • Vandetanib-eluting Radiopaque Embolic Beads in Patients With Resectable Liver Malignancies

    NCT03291379 · start 2017-05-17

    Registered record
    Registry ID
    NCT03291379
    Conditions
    Carcinoma, Hepatocellular; Metastatic Colorectal Cancer
    Interventions
    BTG-002814
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Completed
    Start
    2017-05-17
    Completion
    2019-08-03
    Enrolment
    8

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Hepatocellular; Metastatic Colorectal Cancer
    InterventionBTG-002814
    PhaseEarly phase 1
    Registry statusCompleted

  • Fulvestrant +/- Vandetanib in Advanced Aromatase Inhibitor Resistant Breast Cancer

    NCT02530411 · start 2015-04

    Registered record
    Registry ID
    NCT02530411
    Conditions
    Neoplasms
    Interventions
    Fulvestrant; Vandetanib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2015-04
    Completion
    2020-12
    Enrolment
    160

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNeoplasms
    InterventionFulvestrant; Vandetanib
    PhasePhase 2
    Registry statusUnknown

  • Vandetanib in Advanced NSCLC With RET Rearrangement

    NCT01823068 · start 2014-11-03

    Registered record
    Registry ID
    NCT01823068
    Conditions
    Non Small Cell Lung Cancer
    Interventions
    Vandetanib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-11-03
    Completion
    2018-03-16
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon Small Cell Lung Cancer
    InterventionVandetanib
    PhasePhase 2
    Registry statusCompleted

  • N-of-1 Trial: Actionable Target Identification in Metastatic Cancer for Palliative Systemic Therapy

    NCT02142036 · start 2014-05

    Registered record
    Registry ID
    NCT02142036
    Conditions
    Metastatic Cancer
    Interventions
    EMA-approved ATI based targeted therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-05
    Completion
    2018-08
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Cancer
    InterventionEMA-approved ATI based targeted therapy
    PhasePhase 2
    Registry statusCompleted

  • SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients

    NCT02117167 · start 2014-04-23

    Registered record
    Registry ID
    NCT02117167
    Conditions
    Non-small Cell Lung Cancer Metastatic
    Interventions
    AZD2014; AZD4547; AZD5363; AZD8931; Selumetinib; Vandetanib; Standard maintenance for squamous NSCLC; Pemetrexed; Durvalumab; savolitinib; Olaparib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-04-23
    Completion
    2023-12
    Enrolment
    999

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-small Cell Lung Cancer Metastatic
    InterventionAZD2014; AZD4547; AZD5363; AZD8931 +7 more
    PhasePhase 2
    Registry statusCompleted

  • SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer

    NCT02299999 · start 2014-04-07

    Registered record
    Registry ID
    NCT02299999
    Conditions
    Metastatic Breast Cancer
    Interventions
    AZD2014; AZD4547; AZD5363; AZD8931; Selumetinib; Vandetanib; Bicalutamide; Olaparib; Anthracyclines; Taxanes; cyclophosphamide; DNA intercalators; Methotrexate; vinca alkaloids; Platinum based chemotherapies; Bevacizumab; Mitomycin C; Eribulin; MEDI4736
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Active not recruiting
    Start
    2014-04-07
    Completion
    2025-12
    Enrolment
    1,460

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Breast Cancer
    InterventionAZD2014; AZD4547; AZD5363; AZD8931 +15 more
    PhasePhase 2
    Registry statusActive not recruiting

  • CAPRELSA® REGISTRY: a Belgian Registry to Evaluate the Use of Vandetanib (Caprelsa®) in Current Clinical Practice

    NCT02109250 · start 2014-04

    Registered record
    Registry ID
    NCT02109250
    Conditions
    Metastatic Medullary Thyroid Cancer
    Interventions
    Caprelsa
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2014-04
    Completion
    2015-06
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Medullary Thyroid Cancer
    InterventionCaprelsa
    PhaseNot recorded
    Registry statusCompleted

  • Phase II Trial of Vandetanib in Children and Adults With Wild-Type Gastrointestinal Stromal Tumors

    NCT02015065 · start 2013-12-14

    Registered record
    Registry ID
    NCT02015065
    Conditions
    GIST
    Interventions
    Vandetanib
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-12-14
    Completion
    2019-12-10
    Enrolment
    9

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGIST
    InterventionVandetanib
    PhasePhase 2
    Registry statusCompleted

  • Effect of Vandetanib on Cellular Markers in Invasive Breast Cancer

    NCT01934335 · start 2013-10

    Registered record
    Registry ID
    NCT01934335
    Conditions
    Invasive Breast Cancer
    Interventions
    Vandetanib; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2013-10
    Completion
    2018-12-21
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInvasive Breast Cancer
    InterventionVandetanib; Placebo
    PhasePhase 2
    Registry statusTerminated

  • Evaluation of Efficacy, Safety of Vandetanib in Patients With Differentiated Thyroid Cancer

    NCT01876784 · start 2013-09-17

    Registered record
    Registry ID
    NCT01876784
    Conditions
    Differentiated Thyroid Cancer
    Interventions
    Vandetanib (SAR390530); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-09-17
    Completion
    2022-01-22
    Enrolment
    238

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDifferentiated Thyroid Cancer
    InterventionVandetanib (SAR390530); Placebo
    PhasePhase 3
    Registry statusCompleted

  • Study in Healthy Volunteers to Assess the Pharmacokinetics of Midazolam Administered Alone and in Combination With Vandetanib

    NCT01544140 · start 2012-04

    Registered record
    Registry ID
    NCT01544140
    Conditions
    Healthy Volunteers
    Interventions
    Midazolam; vandetanib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-04
    Completion
    2012-07
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionMidazolam; vandetanib
    PhasePhase 1
    Registry statusCompleted

  • A Phase I Study to Assess the Pharmacokinetics of Metformin When Administered Alone and in Combination With Vandetanib

    NCT01551615 · start 2012-03

    Registered record
    Registry ID
    NCT01551615
    Conditions
    Healthy
    Interventions
    Metformin 1000 mg; Vandetanib 800 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-03
    Completion
    2012-06
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionMetformin 1000 mg; Vandetanib 800 mg
    PhasePhase 1
    Registry statusCompleted

  • Study in Healthy Volunteers to Assess Effect of Omeprazole and Ranitidine on the Pharmacokinetics of Vandetanib

    NCT01539655 · start 2012-02

    Registered record
    Registry ID
    NCT01539655
    Conditions
    Medullary Thyroid Cancer
    Interventions
    vandetanib; omeprazole; ranitidine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-02
    Completion
    2012-09
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMedullary Thyroid Cancer
    Interventionvandetanib; omeprazole; ranitidine
    PhasePhase 1
    Registry statusCompleted

  • Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer

    NCT01191892 · start 2010-06

    Registered record
    Registry ID
    NCT01191892
    Conditions
    Bladder Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Ureter Cancer; Urethral Cancer
    Interventions
    carboplatin; gemcitabine hydrochloride; vandetanib; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2010-06
    Completion
    2016-09-05
    Enrolment
    82

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBladder Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Ureter Cancer; Urethral Cancer
    Interventioncarboplatin; gemcitabine hydrochloride; vandetanib; Placebo
    PhasePhase 2
    Registry statusCompleted